Emerging Company Profile

Tallac: linking antibodies to DNA-triggered innate immunity

Emerging Company Profile: Tallac launches with $62M A round, pipeline of antibody-TLR9 agonist conjugates

Tallac has launched with a $62 million series A round and a solid tumor platform enabling I.V. administration of immunostimulatory TLR9 agonist via conjugation to antibodies.

Tallac